Market news

Support from global health organizations highlights continued development of Dyadic’s C1 and Dapibus platforms for

Imperium AI Founder and CEO Shazir Mucklai will lead an internal review of Dyadic’s biotechnology platforms,

Dyadic International (Nasdaq: DYAI) Advances Next-Generation Biomanufacturing With Global Health Support to Help Turn AI-Designed DNA Into Life-Saving Products

Imperium AI CEO Shazir Mucklai on Major Potential in Dyadic (NASDAQ: DYAI), Calls Board Meeting to Discuss Next Steps

Detailed price information for Dyadic International (DYAI-Q) from The Globe and Mail including charting and trades.

Detailed price information for Dyadic International (DYAI-Q) from The Globe and Mail including charting and trades.

Moby summary of Dyadic International, Inc.'s Q2 2026 earnings call

Motley Fool Press Release.

Dyadic to host earnings call on August 12 at 5:00 pm ETJUPITER, Fla., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial applications, today reported its financial results for the second quarter ended June 30, 2026, highlighting significant progress in product commerciali

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

New agreement builds on commercialization and development of precision-fermented dairy proteins and enzymes while reinforcing Dyadic's diversified commercialization strategyJUPITER, Fla., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) ("Dyadic" or the "Company"), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein solutions across the life sciences, food & nutrition, bioindustrial and biopharmaceutical markets, today announced th

Dyadic Announces to Report Q2 2026 Financial Results August 12, 2026...

Delivery of the Bundibugyo viral antigens to Fondazione Biotecnopolo di Siena (“FBS”) and Scripps Research demonstrates C1's potential to accelerate vaccine and monoclonal antibody development, expand platform adoption, and create future commercial opportunitiesJUPITER, Fla., July 28, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic” or the “Company”), d/b/a Dyadic Applied BioSolutions, today announced that, within approximately 15 days of receiving the plasmids, it de

Detailed price information for Dyadic International (DYAI-Q) from The Globe and Mail including charting and trades.

JUPITER, Fla., July 24, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic” or the “Company”), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein solutions across the life sciences, food and nutrition, bio-industrial and biopharmaceutical markets, today announced that Nasdaq has confirmed that the Company has regained compliance with Nasdaq Listing Rules 5550(a)(2) and 5550(b). The Company’s common stock continues to be listed and t

New initiative builds on EN3ZYME™ launch and highlights scalability of the Dapibus™ platformJUPITER, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) ("Dyadic" or the "Company"), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein solutions across the life sciences, food, nutrition, bio-industrial and biopharmaceutical markets, today announced the expansion of its bio-industrial pipeline with a new proprietary industrial enzy

C1 Monoclonal Antibody Progress for RSV and Malaria Following Full $3.1 Million Gates Foundation Grant FundingJUPITER, Fla., July 07, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic” or the “Company”), d/b/a Dyadic Applied BioSolutions, a biotechnology company focused on the development and commercialization of scalable microbial protein production platforms for use across life sciences, food, nutrition, industrial, and biopharmaceutical sectors, today highlighted con